SynthesisInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2026
Diagnostic accuracy of phosphatase and tensin homolog loss in differentiating between atypical endometrial hyperplasia/endometrioid intraepithelial neoplasia and non-atypical endometrial hyperplasia: A systematic review and meta-analysis.
Synthesis in International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAccurate distinction between atypical endometrial hyperplasia/endometrioid intraepithelial neoplasia (AH/EIN) and non-atypical endometrial hyperplasia (EH) determines whether patients require hysterectomy or can be managed conservatively. Phosphatase and tensin homolog (PTEN) loss has been proposed as an immunohistochemical (IHC) marker to support diagnostic evaluation.
objectivesThis study evaluates the diagnostic value of PTEN IHC for the diagnosis of AH/EIN and to explore how PTEN assessment methods affect diagnostic performance.
methodPubMed, Cochrane Library, ClinicalTrials.gov, Scopus, Embase, MEDLINE, and Web of Science were searched from database inception up to June 1, 2025. Studies reporting PTEN IHC in women with histologically confirmed AH/EIN or non-atypical EH. Two reviewers independently screened records, extracted data, and assessed risk of bias with QUADAS-2. Pooled diagnostic estimates and summary receiver-operating characteristics (SROC) curves were calculated using a bivariate random-effects model with subgroup analysis and the IHC method.
resultsTwenty-seven studies (2274 women) were included. Pooled sensitivity was 58.0% (95% confidence interval [CI], 40.8-73.4) and specificity 84.7% (95% CI, 67-93.8). The diagnostic odds ratio was 3.695 (95% CI, 2.501-5.460), with an area under the SROC of 0.679. The PTEN assessment method based on percentage of stained cells and staining intensity showed the highest the area under the curve of 0.744 among the methods evaluated in the subgroup analysis.
conclusionsPTEN IHC assessment demonstrated good specificity and might serve as a complementary tool in diagnosing AH/EIN, helping to reduce the number of incorrect diagnoses of atypia and unnecessary hysterectomies in clinical practice. Its limited sensitivity precludes its use as a standalone marker. Standardized staining protocols and multi-marker strategies are needed. PROSPERO REGISTRATION: CRD42024607623, registration date the 29 October 2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.